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ABSTRACT  
 The metabolic syndrome (MetS) confers an increased risk of both type 2 diabetes and 
cardiovascular diseases (CVD). Heat shock protein 70 (Hsp70), an intracellular polypeptide, can be 
exposed on the plasma-membrane and/or released into the circulation, eliciting both native and 
immune responses that may contribute to vascular damage. Our aim was to assess if serum anti-
Hsp70 antibody levels were cross-sectionally associated with uncomplicated MetS. A cross-
sectional case-control study from the non-diabetic cohort of the Casale Monferrato Study was 
performed. Subjects with established CVD and/or abnormal renal function were excluded. Case 
subjects (n= 180) were defined as those fulfilling the criteria for the diagnosis of MetS. Control 
subjects (n= 136) were completely free of any component of the MetS. Serum anti-Hsp70 levels 
were measured by immunoenzymatic assay. We found that anti-Hsp70 antibody levels were 
significantly higher in cases than in control subjects [122.6 (89.5-155.6) vs 107.1 (77.3-152.4) 
μg/ml, p=0.04], even after age- and sex-adjustment. In logistic regression analysis, higher levels of 
log-anti-Hsp70 conferred greater odds ratio (OR) for MetS, independently of age and sex. There 
was a statistically significant trend of ORs across quartiles of anti-Hsp70 and values greater than 
108.0 μg/ml conferred a 77% increased OR of MetS as compared with values in the lower quartiles. 
The strength of the association slightly decreased after further adjustment for apolipoprotein B, 
smoke, and albumin excretion rate. In conclusion, our results shows that serum anti-Hsp70 antibody 
levels are independently associated with nascent MetS. 
 
Keywords: metabolic syndrome, heat shock proteins, anti-heat shock protein 70 antibodies, 
cardiovascular disease. 
4 
 
Introduction 
The metabolic syndrome (MetS), which confers an increased risk for both type 2 diabetes and 
cardiovascular disease (CVD), comprises a cluster of cardio-metabolic abnormalities with adiposity, 
insulin resistance, low-grade inflammation, and oxidative stress as its central pathophysiological 
features (Eckel et al., 2005).  
Heat shock protein 70 (Hsp70), an ubiquitous, intracellular, highly conserved polypeptide, is 
important for cytoprotection and cell survival. Hsp70 is induced by oxidative stress in various cell 
types (Hendrick et al., 1995), and by insulin in cardiomyocytes (Li et al., 2006). In type 2 diabetes 
there is a deficiency in both skeletal muscles and liver Hsp70 expression that is believed to 
contribute to the pathogenesis and/or progression of insulin-resistance. Indeed, Hsp70 induction by 
various means enhances insulin sensitivity in both rodents and humans likely through inhibition of 
c-jun terminal kinase activation (Hendrick et al., 1995; Chung et al., 2008).  
In stress conditions, including inflammation, oxidative stress, and endothelial injury, Hsp70 can 
also be exposed on the plasma-membrane and/or released into the circulation. The underlying 
mechanisms are still unclear; however, both passive and active mechanisms have been proposed 
(Joly et al., 2010). In contrast with intracellular Hsp70, extracellular Hsp70 has potent pro-
inflammatory effects, secondary to Hsp70 interaction with toll like receptors resulting in 
inflammatory cytokine production (De Maio, 2011; Zhang et al., 2010, Joly et al., 2010).  
Extracellular Hsp70 can also elicit an autoimmune response with production of anti-Hsp70 
antibodies and this has been implicated in atherosclerosis both progression and severity in humans 
(Pockley et al., 2003). Altered levels of circulating antibodies against Hsp70 have been associated 
with components of MetS, type 2 diabetes, and diabetic micro/macrovascular complications (Wu et 
al., 2001; Ghayour-Mobarhan et al., 2005 and 2007; Gruden et al., 2009). However, there are no 
data on circulating anti-Hsp70 levels in large series of patients with MetS prior to the development 
of CVD and type 2 diabetes. Therefore, the aim of the present study was to investigate if serum 
anti-Hsp70 antibody levels are associated with MetS, uncomplicated by diabetes and CVD. 
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Experimental procedures  
The Casale Monferrato study is an ongoing population-based study started in 1988 in the town of 
Casale Monferrato North-West of Italy. A non-diabetic cohort (n=2,211) was recruited in 2005 
from an age- and sex-stratified sample of 3,700 individuals, aged 45-74 years, randomly identified 
through the files of the resident population, as previously detailed (Bruno et al., 2009). Subjects 
were examined at the diabetes clinic and blood samples collected after overnight fasting, and stored 
at -80° C. Ethics committee approval was obtained and all subjects provided written informed 
consent. A cross-sectional case-control study was designed from the non-diabetic cohort of the 
Casale Monferrato study, after exclusion of subjects (n=659) with CVD, serum creatinine levels ≥2 
mg/dl, and/or high sensitive C reactive protein (hs-CRP) levels ≥ 3mg/l. Cases were those who 
fulfilled the criteria of the updated National Cholesterol Education Program’s Adult Treatment 
Panel III report for the diagnosis of MetS. Control  subjects were selected to be completely free of 
any component of the MetS. Applying these criteria, this yielded 180 cases and 136 controls with 
full data on complications and samples available for analysis. The sample size provides a power of 
82% (α=0.05) to detect a difference in log-anti-Hsp70 within the cohort of at least one-third of 
standard deviation (SD). 
Smoking status was classified as current smoker, never smoker, ex-smoker (smoking cessation at 
least a month prior to the visit). Hypertension was defined as systolic blood pressure >140 mmHg 
and/or diastolic blood pressure >90 mmHg or treatment with antihypertensive drugs. CVD was 
defined as a positive medical history of a cardiovascular event, including myocardial infarction, 
angina pectoris, coronary artery bypass graft and stroke, and/or ischemic changes on a resting 12-
lead electrocardiogram, classified according to the Minnesota Code. The WHO Rose questionnaire 
was also administered and people with symptoms suggestive of CVD underwent further 
investigations to confirm the diagnosis (Bruno et al., 2009).   
Fasting blood samples were taken in the morning visit from all recruited subjects and plasma 
glucose levels measured using the glucose-oxidase method. Triglycerides, total-cholesterol, HDL-
cholesterol, apolipoprotein B, serum creatinine and insulin were measured by standard techniques, 
6 
 
hs-CRP by immunoturbidimetry (Roche-Diagnostic), and albumin excretion rate (AER) by 
nephelometry on single overnight urine collections. Anti-Hsp70 antibody levels were measured in 
serum samples (diluted 1:1000) by ELISA (EKS-750-Enzo Life Sciences) (Ghayour-Mobarhan et 
al., 2005). Assay sensitivity and range were 6.79 ng/ml (6.79-1000 ng/ml) and the intra- and inter-
assay coefficients of variation (CV) were below 10%. Serum IgG levels were determined by 
immunonephelometry (Siemens BN II Analyzer) with anti-IgG reagents and calibrators (Siemens). 
The CV for both intra- and inter-assay was < 4%. 
Data were expressed as mean (SD) or geometric means (interquartile range). Logistic regression 
analysis was used to estimate the odds ratios (ORs) of serum anti-Hsp70 antibody levels for MetS, 
independently of potential confounders and cardiovascular risk factors (age, sex, apoB, smoke, log-
AER). Variables were retained in the final model if they added significantly to the likelihood of 
models or to the estimated coefficients of predictors. To assess pattern of ORs across increasing 
serum anti-Hsp70 antibody levels, they were categorized by the quartile distribution in controls.  
We tested for linear trends across quartiles by entering a single ordinal term into the models. As 
ORs in the first and second anti-Hsp70 quartiles were similar, they were aggregated as the reference 
category in the final analyses and compared with the lowest quartiles. P value of less than 0.05 was 
considered to indicate statistical significance. Analyses were performed with Stata (Stata Release 
10.0, Stata Corporation, College Station, Texas). 
Results  
The study population (n=316) had a mean age of 58.2 years (SD 8.3). As shown in Table 1, cases 
were older than controls and had a greater proportion of men. As expected, mean waist 
circumference, BMI, systolic and diastolic blood pressure, blood glucose, insulin and triglyceride 
levels were greater, while HDL-cholesterol levels lower in cases than in controls. Cases also had a 
more adverse cardiovascular risk profile with significantly higher values of LDL-cholesterol, apoB, 
hs-CRP, and AER. 
Anti-Hsp70 antibodies were measurable in all the 316 samples with right skewed distribution of 
values. Anti-Hsp70 antibody levels were significantly higher in cases than in control subjects 
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(Table 1), even after age- and sex-adjustment (118.2 vs 106.1 p=0.02). However, the difference was 
no longer significant after further adjustment for BMI (p=0.09). Mean IgG levels were similar 
between groups. 
Logistic regression analyses was performed to assess if anti-Hsp70 antibody levels were associated 
with MetS, independently of potential confounders and cardiovascular risk factors. Models showed 
that higher levels of log-anti-Hsp70 conferred greater ORs for MetS (Table 2). This association 
remained statistically significant after adjustment for age and sex (Table 2 - Model 2). A 
statistically significant trend of ORs across quartiles of anti-Hsp70 was observed (p=0.04). Anti-
Hsp70 values in the two upper quartiles (> 108.0 μg/ml) conferred a 77% increased OR of MetS as 
compared with values in the lower quartiles. The strength of the association between anti-Hsp70 
and MetS slightly decreased after further adjustment for apoB, smoke, and AER. 
Discussion 
In this cross-sectional population-based sample of non-diabetic subjects without clinical evidence of 
CVD, we have provided the first evidence of an independent association between anti-Hsp70 
antibody levels and uncomplicated MetS.  
Mean anti-Hsp70 antibody levels were significantly higher in cases than in controls. Excess body 
weight was likely a major determinant of this rise in anti-Hsp70 antibody levels as the difference 
between cases and controls was no longer significant after adjustment for BMI. In logistic 
regression analysis, serum anti-Hsp70 antibody levels greater than 108 μg/ml were associated with 
an almost 80% higher likelihood of MetS with respect to lower values, independently of age and 
sex. Although smoke (Newkirk et al., 2012), hypercholesterolemia (Guisasola et al., 2009), and 
microalbuminuria (Bianchi et al., 2008) have been associated with increased circulating anti-Hsp70 
levels and cases had greater prevalence/levels of these risk factors, the strength of the association 
was only slightly reduced by further adjustment for apoB, smoke, and AER. 
Previous studies have shown an association between circulating anti-Hsp70 antibody levels and  
single parameters of the MetS, such as hypertension, obesity, and dyslipidemia (Wu et al., 2001; 
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Ghayour-Mobarhan et al., 2005 and 2007); however, these clinically-based studies also included 
patients with type 2 diabetes and established CVD, making detangling analysis open to imprecision. 
Indeed, anti-Hsp70 antibody levels are often reduced in patients with CVD, likely because of 
immunocomplex formation (Dulin et al., 2010) and diabetic macro/microvascular complications 
have been associated with lower anti-Hsp70 levels (Gruden et al., 2009). Therefore, in the present 
study we have purposely selected patients with nascent MetS, uncomplicated by diabetes and CVD. 
The underlying cellular mechanisms of anti-Hsp70 antibody rise in patients with nascent MetS 
remains elusive. However, it is likely to reflect a relatively greater exposure, either in the past or in 
the present, to extracellular Hsp70, possibly triggered by MetS-associated oxidative stress, which is 
a known inducer of extracellular Hsp70 release and/or membrane-bound Hsp70 exposure (Zhang et 
al., 2010). This is not in disagreement with recent studies in type 2 diabetes showing a reduced 
Hsp70 expression in insulin-sensitive tissues (i.e. skeletal muscles and liver) and linking this 
downregulation to the pathogenesis of insulin-resistance (Hendrick et al., 1995; Chung et al., 2008). 
Indeed, circulating Hsp70 levels also mirror expression in insulin-independent tissues, where Hsp70 
expression is often enhanced (Yabunaka et al., 1998; Kavanagh et al., 2009). In addition, the dual 
role of intra- and extra-cellular Hsp70 is well recognized and differential mechanisms may regulate 
cytosolic and membrane-bound Hsp70 expression (Joly et al., 2010). In this regard it is noteworthy 
that insulin, whose levels are enhanced in insulin-resistant states, induces Hsp70 expression 
specifically on cardiomyocyte plasma-membranes (Li et al., 2006).  
The rise in anti-Hsp70 antibody levels may play a role in the enhanced CV risk of patients with 
MetS. Indeed, anti-Hsp70 antibodies have been associated with atherosclerosis both progression 
and severity in humans (Pockley et al., 2003). Furthermore, in experimental animals anti-Hsp70 
binding to endothelial Hsp70 triggers an inflammatory response that accelerates atherosclerosis 
(Zhang et al., 2010). On the other hand, the increase in anti-Hsp70 antibody levels may also 
represent a compensatory and protective response because anti-Hsp70 antibodies can prevent the 
deleterious effects of extracellular Hsp70 by clearing circulating Hsp70 and blocking membrane-
bound Hsp70. Indeed, in contrast to cytoprotective intracellular Hsp70, extracellular Hsp70 act as 
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danger signals, eliciting both immune and inflammatory responses, and has deleterious 
inflammatory and pro-atherogenic activity (Zhang et al., 2010).  In line with this hypothesis, a 
recent study, performed in an experimental model of hypertension-induced cardiac hypertrophy, has 
shown that hypertension induces both Hsp70 release and enhanced membrane-bound Hsp70 
expression and that anti-Hsp70 antibodies can abolish cardiac fibrosis by suppressing Hsp70 
conjugation with toll-like receptor 4 and hence to expression of pro-inflammatory and pro-sclerotic 
cytokines (Cai et al., 2010). 
There are certain limitations to our study. First, this is a cross-sectional study and this restricts our 
ability to assess temporal relationships between anti-Hsp70 antibody levels and MetS and to 
identify causal biological mechanisms underlying this association. However, no data on anti-Hsp70 
antibodies and uncomplicated MetS exist; therefore, this study may serve as a reasonable starting 
point to explore this issue. Second, although serum samples were adequately stored, the possibility 
of protein degradation cannot be excluded; however, random misclassification would have biased 
downward our estimates, without affecting significant associations. Third, the presence of CVD was 
assessed based on clinical data and resting ECG; therefore, we cannot exclude the possibility that 
some patients with CVD and normal ECG were erroneously included; however, the WHO Rose 
questionnaire was administered and people with symptoms suggestive of CVD underwent further 
investigations. Last, lack of serum Hsp70 measurement limits interpretation of results; however, 
serum Hsp70 levels only partially reflect actual Hsp70 antigen exposure as extracellular Hsp70 is 
found not only free into the circulation, but also exposed on the cellular plasma-membrane.  
In conclusion, this is the first study providing evidence that serum anti-Hsp70 antibody levels are 
independently associated with MetS, uncomplicated by diabetes and CVD. Further studies are 
required to determine causal relationships and elucidate underlying mechanisms of this association. 
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Table 1. Physical and Clinical Characteristic of the 316 recruited subjects. 
 
 Case subjects Control subjects P 
N 180 136  
Age (years) 60.9 ± 8.6 54.6 ± 6.5 <0.0001 
Males (%) 58.9% 23.5% <0.0001 
BMIa (kg/m2) 29.3 ± 4.6 22.4 ± 2.8 <0.0001 
Waist circumference (cm) 100.6 ± 9.8 77.2 ± 9.3 <0.0001 
Systolic blood pressure (mmHg)  154.0 ± 18.7  118.4 ± 10.1 <0.0001 
Diastolic blood pressure  (mmHg)  94.9 ± 10.6  77.0 ± 6.6 <0.0001 
Hypertension (%)  91.1% 1.5% <0.0001 
Total cholesterol (mmol/l) 222.6 ± 32.5 210.1 ± 32.3 0.003 
LDL-cholesterol (mmol/l) 129.2 ± 35.4  117.8 ± 26.6 0.002 
HDL-cholesterol (mmol/l) 58.1 ± 13.4  76.6 ± 16.7 <0.0001 
Triglycerides (mmol/l) 170 (127-216) 76 (61-89) <0.0001 
ApoB (mg/dl) 106.7 ± 26.1 87.4 ± 18.5 <0.0001 
Glucose (mg/dl) 
Insulin (ng/ml) 
102.0 ± 10.9 
    13.5 (10.1-19.2)
85.8 ± 7.8 
6.0 (4.7-8.2) 
<0.0001 
<0.0001 
AER μg/min 40.0 (25.6-72.9) 30.2 (18.7-47.9) <0.0001 
CRPb (mg/l) 1.4 (0.9-2.1) 0.7 (0.5-1.2)   <0.0001 
Creatinine (mg/dl) 0.86 (0.71-0.97) 0.73 (0.68-0.84) <0.0001 
Smokers                                      no 101 (55.8%) 73 (54.1%) 0.22 
                                                     ex 49 (27.1%) 29 (21.5%)  
                                                    yes 31 (17.1%) 33 (24.4%)  
Anti-Hsp70 (µg/ml) 122.6 (89.5-155.6) 107.1 (77.3-152.4) 0.04 
IgG 11.1 ± 2.5 10.7 ± 2.2 0.19 
aBMI: body mass index; bCRP: C reactive protein 
 
 
 
 
Table 2: Odds ratios for metabolic syndrome by anti-HSP70 values in the case-control study 
within  the Casale Monferrato Study.  
 
 Model 1 Model 2 Model 3 
 OR (95% CI) OR (95% CI) OR (95% CI)
Log-Anti-HSP70 1.67 (1.02-2.73)  2.02 (1.12-3.66) 1.84 (0.97-3.50) 
Anti-HSP70 (µg/ml)           <77.4  1 1 1 
                                  77.4-108.0 1.15 (0.59-2.24) 1.11 (0.51-2.41) 1.06 (0.46-2.47) 
                                 108.1-152.4 1.82 (0.96-3.44) 1.81 (0.87-3.78) 1.81 (0.82-4.02) 
                                   >152.4 1.48 (0.78-2.84) 1.92 (0.90-4.10) 1.62 (0.70-3.73) 
P for trend 0.12 0.04 0.13 
    
Anti-HSP70 (µg/ml)     ≤108.0 1 1 1 
                                      >108.0 1.53 (0.98-2.41) 1.77 (1.05-2.99) 1.67 (0.94-2.96) 
Model 1: unadjusted. Model 2: adjusted for age and sex. Model 3: adjusted for age, sex, smoking, 
apolipoprotein B, albumin excretion rate. 
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